Jianhui Li^1,2

1 Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800;
2 Cuixi Academy of Biotechnology, Zhuji, 311800
Author    Correspondence author
International Journal of Clinical Case Reports, 2020, Vol. 10, No. 4   
Received: 02 Jun., 2020    Accepted: 02 Jun., 2020    Published: 02 Jun., 2020

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Since the outbreak of Novel Coronavirus Pneumonia in late of 2019, it has spread to more than 200 countries and regions around the world as of May 20, 2020,. At the beginning of the epidemic, regarding the naming of the Novel Coronavirus Pneumonia and its pathogen, Chinese doctors and hospitals, official institutions, the public, scholars, and the international organizations such as WHO and ICTV have made great efforts. From initial naming: "unknown pneumonia" to consensus, Novel Coronavirus Pneumonia and its pathogen - Novel Coronavirus were named as COVID-19 and SARS-CoV-2. This paper systematically sorts out the naming process and puts forward some opinions on academic debate, political stigma and racial discrimination of virus naming.

Novel coronavirus; COVID-19; Novel coronavirus pneumonia; SARS-CoV-2; Nomenclature

(The advance publishing of the abstract of this manuscript does not mean final published, the end result whether or not published will depend on the comments of peer reviewers and decision of our editorial board.)